Statement of translational relevance
Introduction
Influence of CART19 doses, lymphodepleting chemotherapy regimens and patient and peripheral blood (PB) ( Figure 1C ). CART19s were transfused directly to patients 210 in escalating doses over a period of 3 consecutive days without any premedication.
211
Each day CART19s were transported to hospital, washed, counted, checked for 212 viability and then prepared for administration to patients, who were then observed 213 closely for at least 2 hours. CRS was graded according to a revised grading system 214 (24). Other toxicities during and after therapy were assessed according to the National excluded from receiving lymphodepletion chemotherapy and CART19s ( Figure 1A ). Figure 3) . These 286 results demonstrate that CART19s induce CR rapidly and effectively in R/R ALL 287 patients both in BM and in extramedullary sites. the 2 groups ( Figure 2B ). In 4 patients, the CAR DNA copies were higher in BM than 303 in PB (Supplementary Figure 4B) . Moreover, CART19s were detectable in the blood 304 and marrow for up to 7 months (Figure 2A ).
305
Paired measurements of CAR DNA copies in BM and PB on day 7 to 10 after 306 CR after allo-HSCT ( Figure 3A) .
327
Of the enrolled 15 patients, 6 patients (40%) died: 3 (20%) owing to severe infection 328 (2 died during the pancytopenia period, and 1 died during the follow-up period) and 3
329
(20%) owing to disease progression or relapse. At 150 days, the OS rate was 65.5%.
330
The LFS rate was 37.8%. The cumulative incidence of relapse in BM or the CNS was 331 54.5%, whereas the cumulative incidence of relapse in BM only was 36.3% ( Figure   332 3B, 3C). The non-relapse mortality (NRM) rate was 7.7% (Supplementary Figure 6) .
333
The median interval of LFS was 143 days (95% CI, 24 to 262 days).
335

Toxicities after CART19s infusion
336
Systemic toxicities-CRS
337
In this trial, 10 of 15 patients (66.7%) experienced CRS. Of these patients, three had 338 grade 1 CRS, 1 had grade 2 CRS, and 6 had grade 3 CRS, as shown in Table 1 and and corticosteroids (n=2), and supportive care plus corticosteroids (n=1) ( Table 1) . No. 5, cytokine levels were much higher in CSF than in serum, with a serum IFN-γ 384 concentration of 152 pg/ml versus a CSF concentration of 2977 pg/ml, and a serum Furthermore, qPCR analysis showed 3032265 CAR copies/μg DNA in CSF versus 387 988747 CAR copies/μg DNA in PB (22). In patient No. 14, no white blood cells
388
(WBCs) were found in the CSF, but the CSF IL-6 level (935 pg/ml) was higher than 389 that in serum (132 pg/ml).
390
The occurrence, management and outcomes in other specific organs are listed in 391   Supplementary Table 3 .
393
Discussion 394
In the current study, we utilized a CART19 strategy to treat Chinese R/R ALL patients.
395
The clinical output of CART19 therapy in enrolled patients was encouraging. This BM in patient 13 could not be detected so n=9). The data represent the mean±SEM.
691
The Mann-Whitney U test was used for statistical analysis. 
